Thymic malignancies

Annals of Oncology

Volumn 19, Issue SUPPL. 7, 2008, Pages

  Smit, E F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IMATINIB; OCTREOTIDE; PREDNISOLONE; VINCRISTINE;

CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTRAST ENHANCEMENT; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MONOTHERAPY; OVERALL SURVIVAL; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL RATE; THYMOMA; THYMUS CANCER; ARTICLE; PATHOLOGY;

HUMANS; THYMOMA; THYMUS NEOPLASMS;

EID: 53449100231     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn471     Document Type: Conference Paper

References (18)

1. de Jong WK, Blauwgeers JL, Schaapveld M et al. Thymic epithelial tumours: A population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 2008; 441: 123-130.
2. Sung YM, Lee KS, Kim BT et al. 18F-FDG PET/CT of thymic epithelial tumors: Usefulness for distinguishing and staging tumor subgroups. J Nucl Med 2006; 47: 1628-1634.
3. Okumura M, Ohta M, Tateyama H et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: A clinical study of 273 patients. Cancer 2002; 94: 624-632.
4. Masaoka A, Yamakawa Y, Niwa H et al. Thymectomy and malignancy. Eur J Cardiothoracic Surg 1994; 8: 251.
5. Chen G, Marx A, Wen-Hu C et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: A clinicopathologic study of 200 thymoma cases from China. Cancer 2002; 95: 420-429.
6. Detterbeck FC. Clinical value of the WHO classification system of thymoma. Ann Thorac Surg 2006; 81: 2328-2334.
7. Giaccone G. Treatment of malignant thymoma. Curr Opin Oncol 2005; 17: 140-146.
8. Blumberg D, Port JL, Weksler B et al. Thymoma: A multivariate analysis of factors predicting survival. Ann Thorac Surg 1995; 60: 908-913.
9. Rena O, Papalia E, Oliaro A et al. Does adjuvant radiation therapy improve disease-free survival in completely resected Masaoka stage II thymoma? Eur J Cardiothoracic Surg 2007; 31: 109-113.
10. Onuki T, Ishikawa S, Yamamoto T et al. Pathologic radioresponse of preoperatively irradiated invasive thymomas. J Thorac Oncol 2008; 3: 270-276.
11. Wright CD, Choi NC, Wain JC et al. Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. Ann Thorac Surg 2008; 85: 385-389.
12. Loehrer et al.
13. Henley JD, Cummings OW, Loehrer PJ. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 2004; 130: 222-224.
14. Suzuki E. Sasaki H, Kawano O et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol 2006; 36: 351-356.
15. Farina G, Garassino MC, Gambacorta M et al. Response of thymoma to cetuximab. Lancet Oncol 2007; 8: 449-450.
16. Strobel P, Hartmann M, Jakob A et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004; 350: 2625-2626.
17. Pan CC, Chen PC, Chiang H et al. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 2004; 202: 375-381.
18. Giaccone G et al. Proc ASCO 2008.